Q1 2026 Management View "I am so pleased that we completed the Amicus acquisition last week... with the addition of 2 innovative therapies, Galafold for Fabry disease and Pombiliti and Opfolda for ...
Adjusted EBITDA -- $514 million for the quarter, supporting consistent performance and cash flow generation. Capital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results